Evidence map›Paper›PMID 35425183›Full record

ReviewRSC advances2022

Advanced applications of cerium oxide based nanozymes in cancer.

Na Feng, Ying Liu, Xianglin Dai, Yingying Wang, Qiong Guo, Qing Li

Open access · goldAbstract readReview
In one paragraph

Review in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 95 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Sericin-coated MnOScientific reports · 2025
    Article
  11. Article
  12. Review
  13. Review
  14. Periodic Table of Immunomodulatory Elements and Derived Two-Dimensional Biomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Na FengDepartment of Molecular Pathology, Application Center for Precision Medicine, The Second Affiliated Hospital of Zhengzhou University Zhengzhou Henan 450052 China 1515012032lq@sina.com.
Ying LiuCenter for Precision Medicine, Academy of Medical Sciences, Zhengzhou University Zhengzhou 450001 China.
Xianglin DaiDepartment of Molecular Pathology, Application Center for Precision Medicine, The Second Affiliated Hospital of Zhengzhou University Zhengzhou Henan 450052 China 1515012032lq@sina.com.
Yingying WangCenter for Precision Medicine, Academy of Medical Sciences, Zhengzhou University Zhengzhou 450001 China.
Qiong GuoDepartment of Molecular Pathology, Application Center for Precision Medicine, The Second Affiliated Hospital of Zhengzhou University Zhengzhou Henan 450052 China 1515012032lq@sina.com.ORCID https://orcid.org/0000-0003-2299-9022
Qing LiDepartment of Molecular Pathology, Application Center for Precision Medicine, The Second Affiliated Hospital of Zhengzhou University Zhengzhou Henan 450052 China 1515012032lq@sina.com.ORCID https://orcid.org/0000-0002-2205-5032
Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cerium oxide nanozymes have emerged as a new type of bio-antioxidants in recent years. CeO

Identifiers

PMID35425183
PMCPMC8979138
OpenAlexW4205683690

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.